Corient Private Wealth LLC Sells 1,277 Shares of Axon Enterprise, Inc $AXON

Corient Private Wealth LLC decreased its position in Axon Enterprise, Inc (NASDAQ:AXON) by 13.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 8,359 shares of the biotechnology company’s stock after selling 1,277 shares during the quarter. Corient Private Wealth LLC’s holdings in Axon Enterprise were worth $4,747,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pure Financial Advisors LLC boosted its position in shares of Axon Enterprise by 6.7% during the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 23 shares in the last quarter. Tobam boosted its stake in Axon Enterprise by 17.3% in the 4th quarter. Tobam now owns 5,833 shares of the biotechnology company’s stock worth $3,313,000 after purchasing an additional 859 shares during the period. Clearwave Capital LLC bought a new position in Axon Enterprise during the 4th quarter worth about $325,000. Sit Investment Associates Inc. increased its holdings in Axon Enterprise by 23.1% during the 4th quarter. Sit Investment Associates Inc. now owns 8,374 shares of the biotechnology company’s stock worth $4,756,000 after purchasing an additional 1,574 shares in the last quarter. Finally, Tempo Wealth LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at about $239,000. 79.08% of the stock is owned by institutional investors.

Insider Activity at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 564 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the sale, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. This represents a 13.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Joshua Isner sold 13,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the sale, the president directly owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This represents a 7.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 38,989 shares of company stock worth $19,090,083 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.

Axon Enterprise Trading Up 4.6%

Shares of AXON stock opened at $465.12 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The stock has a market cap of $37.49 billion, a P/E ratio of 186.79, a price-to-earnings-growth ratio of 8.09 and a beta of 1.45. The stock has a 50 day simple moving average of $420.65 and a 200 day simple moving average of $482.08. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company’s revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the company earned $1.47 EPS. On average, research analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AXON. Morgan Stanley set a $600.00 price objective on Axon Enterprise in a research report on Thursday, May 7th. Barclays dropped their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $674.00 target price on shares of Axon Enterprise in a research note on Monday, June 15th. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.